𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat

✍ Scribed by J. D. Salamone; M. D. Lalies; S. L. Channell; S. D. Iversen


Publisher
Springer
Year
1986
Tongue
English
Weight
517 KB
Volume
88
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

✦ Synopsis


Pilocarpine administered in doses of 1.25-10.0 mg/kg (IP) produced a variety of mouth movements in the rat. The most frequent of these movements was a chewing behaviour, which increased up to a mean frequency of over 40 per min at the highest doses. Tongue protrusion and gaping also showed dose-dependent increases. Yawning tended to increase in some doses, though these increases were not significant, and yawning was relatively infrequent. Pre-treatment with scopolamine reduced these responses, while pre-treatment with methyl scopolamine did not. Injections of oxotremorine or arecoline, but not carbachol, produced dose-related increases in mouth movements similar to those produced by pilocarpine. These results suggest that mouth movements in the rat are caused by stimulation of central muscarinic receptors. This may prove to be an important behavioural sign of central cholinomimetic activity.


πŸ“œ SIMILAR VOLUMES


Pharmacological in vitro characterizatio
✍ Eddi Meier; Kristen Frederiksen; Mogens Nielsen; Hanne LΓΈve LembΓΈl; Henrik Peder πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 210 KB πŸ‘ 1 views

The arecoline bioisostere, Lu 25-109-T, displays a pharmacological profile of a partial muscarinic agonist with a several-fold higher affinity for cortical M 1 receptors than for brain stem M 2 receptors and salivary glands M 3 receptors. The compound is selective for muscarinic receptors as it show

Failure of muscarinic blockade to antago
✍ Emily M. Santori; Dennis E. Schmidt; Peter W. Kalivas; Akira Horita πŸ“‚ Article πŸ“… 1981 πŸ› Springer 🌐 English βš– 391 KB

In the rat, the antimuscarinics atropine and scopolamine failed to block the reduction in pentobarbital-induced sleep time produced by either thyrotropin-releasing hormone (TRH) or MK-771 (a TRH analog). Previous reports have indicated that the marked analeptic effect produced by TRH is antagonized